CellPoint enables clinicians to treat hematological malignancies by retargeting patient immune cells at the point-of-care.
Get in touch or visit our website: https://cellpoint.bio
Get in touch or visit our website: https://cellpoint.bio
Location: Netherlands, South Holland, Oegstgeest
Employees: 11-50
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | ND CAPITAL | nd.capital |
Mentions in press and media 3
| Date | Title | Description |
| 06.04.2022 | Pregene Enters into Innovative Partnership with CellPoint to Develop anti-BCMA CAR-T Cell Therapy in Europe and the US | SHENZHEN, China and LEIDEN, Netherlands, April 6, 2022 /PRNewswire/ -- Shenzhen Pregene Biopharma, a clinical-stage biopharmaceutical company engaged in discovering, developing, manufacturing and commercializes innovative medicines and Cell... |
| 06.01.2022 | UK paytech CellPoint raises $25m to expand internationally | Paytech CellPoint Digital has secured a $25 million investment in an equity financing round. CellPoint Digital CEO Kristian Gjerding The funding round was provided by Toscafund and its private equity arm Penta Capital, following a series of... |
| 30.11.2021 | CellPoint and Hypertrust Patient Data Care co-develop xCellit platform for cell therapies at the point-of-care | MEDIA, Pa. (PRWEB) November 30, 2021 CellPoint and Hypertrust Patient Data Care (HPDC) today announced the launch of xCellit. The xCellit system was co-developed to make autologous cell therapies available more rapidly and efficiently by fa... |